Please use this identifier to cite or link to this item: doi:10.22028/D291-34594
Title: Value of Combined PET Imaging with [18F]FDG and [68Ga]Ga-PSMA-11 in mCRPC Patients with Worsening Disease during [177Lu]Lu-PSMA-617 RLT
Author(s): Khreish, Fadi
Ribbat, Kalle
Bartholomä, Mark
Maus, Stephan
Stemler, Tobias
Hierlmeier, Ina
Linxweiler, Johannes
Schreckenberger, Mathias
Ezziddin, Samer
Rosar, Florian
Language: English
Title: Cancers
Volume: 13
Issue: 16
Publisher/Platform: MDPI
Year of Publication: 2021
Free key words: radioligand therapy
metastatic castration-resistant prostate cancer
DDC notations: 610 Medicine and health
Publikation type: Journal Article
Abstract: Despite the promising results of prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) in metastatic castration-resistant prostate cancer (mCRPC), some patients show worsening disease during PSMA-RLT. We investigated the value of combined [18F]FDG and [ 68Ga]Ga-PSMA-11 PET imaging in this setting. In n = 29 mCRPC patients with worsening disease after a median of four cycles of [177Lu]Lu-PSMA-617 RLT, combined [18F]FDG and [68Ga]Ga-PSMA11 PET imaging was performed to detect [18F]FDG-avid lesions with low or no PSMA expression (mismatch lesions). To evaluate prognostic implication of mismatch, survival analyses regarding presence, location, and [18F]FDG PET-derived parameters such as SUVmax, metabolic tumor volume (MTVm), and total lesion glycolysis (TLGm) of mismatch findings were performed. Seventeen patients (59%) showed at least one mismatch metastasis. From the time point of combined PET imaging, the median overall survival (OS) of patients with mismatch findings was significantly (p = 0.008) shorter than those without (3.3 vs. 6.1 mo). Patients with a high MTVm revealed a significantly (p = 0.034) shorter OS of 2.6 mo than patients with low MTVm (5.3 mo). Furthermore, patients with hepatic mismatch showed a significantly (p = 0.049) shorter OS than those without (2.9 vs. 5.3 mo). Difference in OS regarding SUVmax and TLGm was not significant. In mCRPC patients with worsening disease during PSMA-RLT, combined [18F]FDG and [68Ga]Ga-PSMA-11 PET imaging is essential to identify mismatch findings, as these are associated with poor outcomes requiring a change in therapy management.
DOI of the first publication: 10.3390/cancers13164134
Link to this record: urn:nbn:de:bsz:291--ds-345949
ISSN: 2072-6694
Date of registration: 30-Aug-2021
Description of the related object: Supplementary Materials
Related object:
Faculty: M - Medizinische Fakultät
Department: M - Radiologie
M - Urologie und Kinderurologie
Professorship: M - Prof. Dr. Samer Ezziddin
M - Keiner Professur zugeordnet
Collections:SciDok - Der Wissenschaftsserver der Universität des Saarlandes

Files for this record:
File Description SizeFormat 
cancers-13-04134.pdf1,63 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons